| Literature DB >> 23285060 |
David J Leibly1, Trang Nhu Nguyen, Louis T Kao, Stephen N Hewitt, Lynn K Barrett, Wesley C Van Voorhis.
Abstract
Insoluble recombinant proteins are a major issue for both structural genomics and enzymology research. Greater than 30% of recombinant proteins expressed in Escherichia coli (E. coli) appear to be insoluble. The prevailing view is that insolubly expressed proteins cannot be easily solubilized, and are usually sequestered into inclusion bodies. However, we hypothesize that small molecules added during the cell lysis stage can yield soluble protein from insoluble protein previously screened without additives or ligands. We present a novel screening method that utilized 144 additive conditions to increase the solubility of recombinant proteins expressed in E. coli. These selected additives are natural ligands, detergents, salts, buffers, and chemicals that have been shown to increase the stability of proteins in vivo. We present the methods used for this additive solubility screen and detailed results for 41 potential drug target recombinant proteins from infectious organisms. Increased solubility was observed for 80% of the recombinant proteins during the primary and secondary screening of lysis with the additives; that is 33 of 41 target proteins had increased solubility compared with no additive controls. Eleven additives (trehalose, glycine betaine, mannitol, L-Arginine, potassium citrate, CuCl(2), proline, xylitol, NDSB 201, CTAB and K(2)PO(4)) solubilized more than one of the 41 proteins; these additives can be easily screened to increase protein solubility. Large-scale purifications were attempted for 15 of the proteins using the additives identified and eight (40%) were prepared for crystallization trials during the first purification attempt. Thus, this protocol allowed us to recover about a third of seemingly insoluble proteins for crystallography and structure determination. If recombinant proteins are required in smaller quantities or less purity, the final success rate may be even higher.Entities:
Mesh:
Substances:
Year: 2012 PMID: 23285060 PMCID: PMC3527557 DOI: 10.1371/journal.pone.0052482
Source DB: PubMed Journal: PLoS One ISSN: 1932-6203 Impact factor: 3.240
Complete additive and buffer list at final concentrations.
| Additives 1–40 | Additives 41–80 | Additives 81–120 | Buffer Conditions 1–24 |
| 100 mM Ammonium Sulfate | 0.1% Tween 80 | 0.2% Dimethylethylammoniumpropane sulfonate (NDSB 195) | 25 mM MES pH 6.0 |
| 10 mM Barium Chloride | 0.01% Triton X-100 | 0.2% 3-(1-Pyridino)-1-propane sulfonate(NDSB 201) | 25 mM MES pH 6.0, 5 mM TCEP |
| 10 mM Barium Iodide | 0.01% CTAB | 2.0% Benzamidine HCl | 25 mM MES pH 6.0, 200 mM NaCl |
| 10 mM Cadmium Chloride* | 0.05% Lauryl Sulfobetaine | 0.1% Formamide | 25 mM MES pH 6.0, 200 mM NaCl, 5 mM TCEP |
| 20 mM Calcium Chloride | 0.05% Brij 56 | 100 mM Urea | 25 mM MES pH 6.0, 400 mM NaCl |
| 100 mM Cesium Chloride | 0.05% Zwittergent 3-08 | 100 mM Guanidine HCl | 25 mM MES pH 6.0, 400 mM NaCl, 5 mM TCEP |
| 10 mM Cobalt chloride# | 10 mM Triethanolamine HCl | 50 mM Tricine | 25 mM MES pH 6.0, 600 mM NaCl |
| 10 mM Copper (II) chloride*# | 10 mM Spermine | 30 mM EPPS | 25 mM MES pH 6.0, 600 mM NaCl, 5 mM TCEP |
| 10 mM Gadolinium bromide*# | 100 mM Sarcosine | 30 mM Tris pH 8.0 | 25 mM Hepes pH 7.0 |
| 10 mM Holmium chloride*# | 10 mM Trimethylamine N-oxide | 2.5 mM SAM | 25 mM Hepes pH 7.0, 5 mM TCEP |
| 10 mM Lanthanum acetate# | 10 mM Glycine betaine | Vitamin B12# | 25 mM Hepes pH 7.0, 200 mM NaCl |
| 100 mM Lithium chloride | 2.0% Mannitol | 10 mM Biotin | 25 mM Hepes pH 7.0, 200 mM NaCl, 5 mM TCEP |
| 100 mM Lithium sulfate | 2.0% Erythritol | 50 uM Riboflavin | 25 mM Hepes pH 7.0, 400 mM NaCl |
| 10 mM Magnesium chloride | 5.0% Trehalose | 10 mM α-Cyclodextrin | 25 mM Hepes pH 7.0, 400 mM NaCl, 5 mM TCEP |
| 10 mM Manganese chloride | 5.0% Glucose | 10 mM choline chloride | 25 mM Hepes pH 7.0, 600 mM NaCl |
| 100 mM Potassium chloride | 5.0% Sucrose | 0.5% Brij 35 | 25 mM Hepes pH 7.0, 600 mM NaCl, 5 mM TCEP |
| 100 mM Potassium citrate | 5.0% Xylitol | 0.5% LDAO | 25 mM Tris pH 8.0 |
| 5 mM Samarium bromide*# | 1.5% β-cyclodextrin | 0.5% Triton X-100 | 25 mM Tris pH 8.0, 5 mM TCEP |
| 10 mM Samarium chloride*# | 0.5% 1,2,3-heptanetriol | 0.5% CTAB | 25 mM Tris pH 8.0, 200 mM NaCl |
| 50 mM Sodium fluoride | 3.0% 6-aminocaproic acid | 0.5% Lauryl Sulfobetaine | 25 mM Tris pH 8.0, 200 mM NaCl, 5 mM TCEP |
| 100 mM Sodium malonate | 3.0% Ethylene glycol | 0.5% Tween 60 | 25 mM Tris pH 8.0, 400 mM NaCl |
| 10 mM Yttrium chloride*# | 3.0% Gamma butyrolactone | 0.5% Brij 56 | 25 mM Tris pH 8.0, 400 mM NaCl, 5 mM TCEP |
| 10 mM Yttrium nitrate*# | 100 mM Glycine | 0.5% Zwittergent 3-08 | 25 mM Tris pH 8.0, 600 mM NaCl |
| 10 mM Sodium selenite | 10 mM Gly-Gly-Gly | 0.5% Brij 93 | 25 mM Tris pH 8.0, 600 mM NaCl, 5 mM TCEP |
| 5 mM Zinc chloride* | 5.0% Jeffamine M-600# | 0.5% Octylβ-D-glucopyranoside | |
| 10 mM Nickel chloride* | 5.0% PEG 300# | 0.5% N-lauryl sarcosine | |
| 10 mM Sodium molybdate | 5.0% PEG 4000 | 0.5% ASB-14 | |
| 10 mM Iron (III) Chloride*# | 5 mM DTT | 100 mM Dipotassium phosphate | |
| 10 mM Ammonimun nitrate | 5 mM BME | 375 mM L-Arginine | |
| 10 mM Sodium thiocyanate | 5 mM TCEP | 0.5 M Proline | |
| 10 mM Ammonium acetate | 5 mM EDTA | 1 M Glycine betaine | |
| 10 mM Potassium nitrate | 5 mM EGTA pH 8.0 | 1 M 3-(1-Pyridino)-1-propane sulfonate (NDSB 201) | * Additive was made in dH2O onlyFinal pH was not adjusted |
| 10 mM Sodium acetate | 10 mM ATP | 1 M Xylitol | # Samples containing this additive must be diluted prior to SDS-PAGE analysis |
| 0.2% ASB-14 | 10 mM ADP | 0.5 M Mannitol | |
| 0.05% Brij 93 | 10 mM GTP | 0.7 M Trehalose | |
| 0.05% Octyl β-D-glucopyranoside | 75 mM L-Arginine | 50 mM α-Cyclodextrin | |
| 0.01% Brij 35 | 50 mM Taurine | 2 M Formamide | |
| 0.05% LDAO | 5 mM Glutamic Acid | 1 M Dimethylethylammoniumpropane sulfonate (NDSB 195) | |
| 0.05% N-lauryl sarcosine | 100 mM Proline | 1 M Trimethylamine N-oxide | |
| 0.1% SDS | 100 mM Imidazole | 100 mM Triethylamine |
Figure 1Flowchart of the additive screen in the context of high-throughput structural genomics.
The target open reading frame is cloned into SSGCID vectors then expression testing is performed [25]. If the protein is soluble it is entered into our standard purification pipeline [28]. High priority insoluble proteins enter into additive screening. One two-liter culture is grown to obtain pelleted E. coli expressing the recombinant proteins for the screens, and then the 144 condition primary screen is conducted. All conditions that show an increase in solubility are subjected to a secondary screen for confirmation. Successful secondary screen proteins are then purified with additives and those that are >95% pure and yield >5 mg enter into crystal trials. In the event that the secondary screen fails, the results from the primary screen may be used to guide the creation of new additive and buffer combinations for custom screening.
Screening step success rate.
| Step | Number | Overall Success % |
| Proteins Selected | 45 | N/A |
| Proteins Expressed | 41 | 100 |
| Proteins with >2 primary hits | 34 | 83 |
| Proteins Soluble in Secondary | 33 | 80 |
| Soluble in >2 Additive Conditions | 16 | 39 |
Individual protein screening and scale-up results.
| Species | Protein | Uniprot ID | Screening and Scale-upResult | Solubilization Additive |
|
| Lanosterol 14-alpha-demethylase | Q68HC5 | Failed to express | |
|
| 14-alpha sterol demethylase Cyp51B | Q96W81 | Solubilized | Trehalose |
|
| 14-alpha sterol demethylase Cyp51A | Q4WNT5 | Screen failed to yield soluble | |
|
| Sensory transduction histidine kinase, putative | O51381 | Solubilized, purified, crystal trials | Trehalose, Mannitol |
|
| Sensor protein | Q3JG94 | Solubilized, purified, crystal trials | Trehalose |
|
| Sensor protein | Q3JS34 | Solubilized, purified, crystallized, did not diffract | Trehalose |
|
| Pentapeptide repeat family protein | Q3JL51 | Solubilized | Trehalose, L-Arginine |
|
| Metallopeptidase domain protein | Q3JGM7 | Solubilized, self-cleaving, purified, crystal trials | Trehalose |
|
| Lanosterol 14-alpha demethylase | Q9UVT4 | Screen failed to yield soluble | |
|
| Lanosterol 14-alpha demethylase | P50859 | Screen failed to yield soluble | |
|
| Cytochrome P450 51 | E9DGX7 | Failed to express | |
|
| Cytochrome P450 51 | E9DIY7 | Solubilized | Trehalose |
|
| Metalloprotease 1 | Q71H76 | Solubilized | Xylitol |
|
| Proline-rich antigen 2 | Q6K1L8 | Solubilized, purified, yielded diffracting protein crystals, but structure not solved yet | Potassium Citrate |
|
| Proline-rich antigen 5 | Q3Y5I2 | Solubilized, purified, crystal trials | Trehalose |
|
| Lanosterol 14 alpha-demethylase | Q09GQ2 | Solubilized, purified, crystal trials | Mannitol, SDS |
|
| Cytochrome P450 51 | Q9UVC3 | Solubilized | Octyl β-D-glucopyanoside |
|
| C2 domain-ontaining protein | C4M344 | Solubilized | Mannitol & Potassium Citrate |
|
| PRMT7 homologue | C4LST3 | Solubilized | Samarium (III) |
|
| Putative uncharacterized protein | C4LX71 | Solubilized | Trehalose |
|
| Lanosterol 14-alpha-demethylas | Q874Q6 | Solubilized | Xylitol |
|
| Elongation factor 1-alpha | Q95VF2 | Solubilized | Trehalose & Glycine betaine |
|
| FADE29 | P71858 | Screen failed to yield soluble | |
|
| LPPN Rv2270 | Q50693 | Solubilized | Trehalose, L-Arginine |
|
| Hypothetical protein Rv3172c | O53322 | Failed during purification | |
|
| Uncharacterized protein Rv3683 | O69651 | Solubilized | Trehalose |
|
| Lanosterol 14-alpha demethylase | Q875H2 | Solubilized | Trehalose, Proline, Glycine betaine, NDSB 201, Mannitol |
|
| Lanosterol 14-alpha demethylase | P10614 | Solubilized | Glycine betaine |
|
| Rhoptry kinase family protein ROP22 | B6KP01 | Solubilized | Copper (II) chloride |
|
| Rhoptry kinase family protein ROP1 | B6KEY1 | Failed during purification | |
|
| Rhoptry kinase family protein ROP28 | B6KB67 | Solubilized | Copper (II) chloride |
|
| Rhoptry kinase family protein ROP40 | B6KL15 | Solubilized | Copper (II) chloride |
|
| Membrane skeletal protein IMC1 | B6KJM2 | Solubilized | Arginine, Trehalose |
|
| Rhoptry protein ROP7 | B6KR07 | Solubilized | Trehalose, CTAB |
|
| Malaria antigen, putative | B6KFD4 | Screen failed to yield soluble | |
|
| Surface antigen P22 | B6KD48 | Solubilized, purified, crystal trials | TCEP |
|
| Hsp20/alpha crystallin domain-containing protein | B6KKL2 | Solubilized | Trehalose, NDSB 195, Mannitol |
|
| TgDIP13 | B6KUH1 | Failed to express | |
|
| Receptor for activated C kinase, RACK protein | B6KSU1 | Screen failed to yield soluble | |
|
| Unnamed apical complex protein | B6KDE9 | Solubilized | Potassium Citrate, ASB-14, Trehalose, Glycine betaine, Proline, K2HPO4, Mannitol |
|
| TgDCX | B6KAS6 | Solubilized | Trehalose, L-Arginine, Proline, NDSB 201, Mannitol, Formamide |
|
| Unnamed apical complex protein | B6K951 | Solubilized | Potassium Citrate, Trehalose, |
|
| Unnamed apical complex protein | B6KBK7 | Solubilized | Trehalose, L-Arginine, Proline |
|
| Unnamed apical complex protein | B6KN56 | Failed to express | |
|
| Unnamed apical complex protein | B6K9R8 | Solubilized | Trehalose, Triton X-100, CTAB |
Protein previously appeared totally insoluble.
Top additives results.
| Additive | Primary Hits | Soluble Protein (Secondary Screen) |
| 0.75 M Trehalose | 25 | 21 |
| 1 M Glycine betaine | 21 | 4 |
| 0.5 M Mannitol | 18 | 7 |
| 0.1 M Potassium citrate | 12 | 4 |
| 1 M Trimethylamine N-Oxide | 12 | 0 |
| 0.5 M Proline | 11 | 4 |
| 1 M Dimethylethylammoniumpropane sulfonate (NDSB 195) | 11 | 1 |
| 0.375 M L-Arginine | 8 | 6 |
| 1 M Xylitol | 8 | 2 |
| 0.01 M Sodium selenite | 8 | 0 |
| 1 M 3-(1-Pyridino)-1-propane sulfonate(NDSB 201) | 6 | 2 |
| 0.1 M Dipotassium phosphate | 5 | 2 |
| CuCl2 | 3 | 3 |
| CTAB | 3 | 2 |
Figure 3The top performing additive molecular structures.
Presented are the molecular structures of the top performing additives. The number of proteins soluble with each additive is presented in table 4.
Figure 2SDS-PAGE gels from the screen of T. gondii Hsp20.
(A) Presented is one of the six SDS-PAGE gels from the primary screening experiments of Hsp20 from Toxoplasma gondii. Six screening gels are performed per protein to screen all 144 unique cell lysis conditions, 24 conditions per gel. Each gel is run with the protein-lysed apo (without additives) on the far left side of the gel. “Std. Total” is total cell lysate, lysed without additives. “Std. Soluble” is the soluble fraction of the non-additive lysed cells. The lanes between ‘A1’ and ‘B12’ are the 24 conditions screened on this gel. The expected molecular weight of the recombinant protein, Toxoplasma gondii Hsp20, is indicated with the arrow. The conditions that appeared to increase solubility and were subsequently re-screened are LDAO (A2), L-Arginine (B2), L-Proline (B3), Glycine Betaine (B4), Mannitol (B7), Trehalose (B8), NDSB 195 (B11), and Trimethylamine N-Oxide (B12). (B) SDS-PAGE gel image shows the individual secondary screen for the Toxoplasma gondii Hsp20 from figure 1A. The Toxoplasma Hsp20 protein has an ‘Apo’ control that was lysed without any additives present. Additive conditions are in the lane to the right of each Apo. Lanes marked ‘T’ are the total cell lysate, lanes marked ‘S’ are the soluble fraction for each condition. The overexpressed protein band at ∼28 kDa is the protein of interest. Conditions B8 (Trehalose) and B11 (NDSB 195) proved to be the best in solubilizing the protein, where close to 100% of the protein was present in the soluble fraction when compared to the total cell lysate, as opposed to conditions B2–B7 where there is a clear distinction between the relative amount of recombinant protein present in the soluble fraction compared to the total fraction.
Figure 4SDS-PAGE of the purification of Coccidioides posadasii Proline-Rich antigen 2 (Prp2).
SDS-PAGE gels from Prp2, which was purified in the presence of 100 mM potassium citrate. The resulting protein resulted in diffraction quality crystals. On the left are samples from the metal affinity purification step. Lanes are as follows: “M” molecular weight standards with the corresponding weights in kDa indicated; “T” total cell lysate; “S” soluble cell lysate after centrifugation; “FT” flow through from the affinity purification column; “E” eluate from the affinity column. The band corresponding to Prp2 is marked the arrow “P”, the arrow “L” is lysozyme added during lysis. Select size exclusion chromatography fractions were analyzed via SDS page, the fraction deemed the purest concentrated for crystal trials are boxed. This protein formed diffracting crystals but the structure has not yet been solved.
Figure 5Proposed mechanism for rescue of recombinant protein solubility.
We hypothesize that up to 80% of the seemingly insoluble recombinant proteins are in a partially folded state and reside in the E. coli cytosol. If lysed in a non-ideal buffer, the proteins unfold, resulting in aggregates of insoluble protein. When the sample is centrifuged to separate the soluble fraction, the protein aggregates are present in the insoluble cell pellet. If the additives are present during cell lysis, they can either stabilize the proteins from partially unfolding, preventing protein-protein interactions, or aid as chemical chaperones, leading to the properly folded and non-aggregated state. When centrifuged there are minimal protein aggregates and the recombinant protein remains in the soluble fraction.